Shimauchi A, Iwama E, Ibusuki R, Tsutsumi H, Shibahara D, Otsubo K, Yoneshima Y, Tanaka K, Okamoto I

Enhanced HER2 internalization by clathrin-dependent endocytosis in non-small cell lung cancer positive for HER2 mutations.

Br J Cancer 133(7): 976-985, 2025Pubmed

Mizusaki S, Yoneshima Y, Iwama E, Nakashima T, Ibusuki R, Shibahara D, Otsubo K, Tanaka K, Okamoto I

NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors.

Cancer Immunol Immunother 74(7): 211, 2025Pubmed

Ninomiya T, Kemmotsu N, Mukohara F, Magari M, Miyamoto A, Ueda Y, Ishino T, Nagasaki J, Fujiwara T, Yamamoto H, Hayashi H, Tachibana K, Ishida J, Otani Y, Tanaka S, Toyooka S, Okamoto I, Togashi Y

Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy.

Cancer Res 85(6): 1082-1096, 2025Pubmed

Utsumi T, Mizuta H, Seto Y, Uchibori K, Nishio M, Okamoto I, Katayama R

AXL-mediated drug resistance in ALK-rearranged NSCLC enhanced by GAS6 from macrophages and MMP11 positive fibroblasts.

Cancer Sci 116(4): 1034-1047, 2025Pubmed

Shiraishi Y, Shimose T, Tsuchiya-Kawano Y, Ishii H, Mizuno K, Toi Y, Daga H, Ito K, Iyama S, Taniguchi H, Morinaga R, Harada T, Inoue H, Misumi Y, Naoki K, Tobino K, Izumi M, Omori S, Tsumura S, Yamanaka Y, Sakata Y, Miura S, Mizutani H, Oki M, Iwama E, Otsubo K, Okamoto I

Platinum plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multicenter, single-arm phase II trial (LOGiK2001, SPEED).

ESMO Open 10(7): 105325, 2025Pubmed

Shiraishi Y, Shimose T, Tachihara M, Tsuchiya-Kawano Y, Morinaga R, Inoue H, Toi Y, Yamada T, Yamaguchi M, Kashiwabara K, Tobino K, Ishii H, Sakata Y, Inaba M, Nakashima K, Chibana K, Fukui T, Izumi M, Saito R, Ishii H, Omori S, Ogusu S, Furuyama K, Miura S, Harada T, Okamoto I

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).

Eur J Cancer 229: 115779, 2025Pubmed

Shiraishi Y, Shimose T, Tobino K, Toi Y, Wakuda K, Matsumoto H, Sakaguchi T, Mashimoto A, Hayashi H, Ebina-Shibuya R, Mori M, Taniguchi Y, Kuyama S, Kashiwabara K, Furuyama K, Yoshimine K, Kimura Y, Kobayashi H, Kishimoto J, Okamoto I

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002).

Lung Cancer 203: 108543, 2025Pubmed

Iwama E, Sakai K, Harada T, Kanda S, Sugawara S, Yokoyama T, Taniguchi H, Tanaka K, Toyozawa R, Koyama K, Zenke Y, Kida G, Nishioka Y, Yokouchi H, Hirose M, Nishio K, Yamamoto N, Ohe Y, Okamoto I

Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations.

Lung Cancer 208: 108756, 2025Pubmed

Ibusuki R, Iwama E, Shimauchi A, Kawano H, Mizusaki S, Nakamura S, Miyazaki Y, Inutsuka Y, Hashisako M, Harada T, Tsuchiya-Kawano Y, Tsutsumi H, Nakanishi T, Nakagaki N, Koga Y, Kimura S, Mashimoto S, Shibahara D, Otsubo K, Yoneshima Y, Tanaka K, Oda Y, Okamoto I

IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer.

Mol Cancer 24(1): 272, 2025Pubmed

Miyazaki Y, Iwama E, Ogata H, Ibusuki R, Shibahara D, Otsubo K, Shiaraishi Y, Yoneshima Y, Torisu K, Okamoto I

Renal dysfunction during osimertinib treatment in patients with non-small cell lung cancer positive for EGFR mutations.

Respir Investig 63(3): 438-443, 2025Pubmed

Nakashima K, Otsubo K, Tsuchiya-Kawano Y, Mikumo H, Iwama E, Harada E, Okamoto I

Suitability of Frozen Pleural Fluid Pellets for Next-Generation Sequencing-Based Driver Gene Testing in Non-Small Cell Lung Cancer.

Thorac Cancer 16(11): e70107, 2025Pubmed

Kishikawa Y, Otsubo K, Shibahara D, Shiraishi Y, Yoneshima Y, Iwama E, Okamoto I

Remarkable response to crizotinib in a patient with advanced lung adenocarcinoma harboring the MPRIP-ROS1 fusion gene: A case report.

Respir Med Case Rep 56: 102243, 2025Pubmed

Shibahara D, Tanaka K, Togao O, Shiraishi Y, Yoneshima Y, Iwama E, Yoshitake T, Ishigami K, Okamoto I

Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer.

Clin Lung Cancer 25(6): 581-586.e3, 2024Pubmed

Tsuchiya-Kawano Y, Shiraishi Y, Tanaka K, Tachihara M, Saito R, Okamoto T, Sugasaki N, Nakatomi K, Kiyomi F, Okamoto I

Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004).

Eur J Cancer 212: 115052, 2024Pubmed

Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I

Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.

JAMA Oncol 10(3): 315-324, 2024Pubmed

Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, Azuma K, Hara S, Niho S, Morita R, Yamaguchi M, Yokoyama T, Yoh K, Kurata T, Okamoto H, Okamoto M, Kijima T, Kasahara K, Fujiwara Y, Murakami S, Kanda S, Akamatsu H, Takemoto S, Kaneda H, Kozuki T, Ando M, Sekino Y, Fukuda H, Ohe Y, Okamoto I

Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.

Lancet Respir Med 12(11): 877-887, 2024Pubmed

Ibusuki R, Iwama E, Shimauchi A, Tsutsumi H, Yoneshima Y, Tanaka K, Okamoto I

TP53 gain-of-function mutations promote osimertinib resistance via TNF-α-NF-κB signaling in EGFR-mutated lung cancer.

NPJ Precis Oncol 8(1): 60, 2024Pubmed

Inutsuka Y, Iwama E, Shiraishi Y, Yoneshima Y, Shibahara D, Tanaka K, Okamoto I

Osimertinib readministration for central nervous system metastases in non-small cell lung cancer positive for EGFR activating mutations.

Respir Investig 62(3): 334-338, 2024Pubmed

Shiraishi Y, Tokito T, Toyozawa R, Inagaki C, Nokihara H, Kawashima Y, Ohe Y, Okamoto I

Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.

J Thorac Oncol 19(2): 337-343, 2024Pubmed

Sakoda S, Tanaka K, Koga Y, Mikumo H, Tuchiya-Kawano Y, Harada E, Tamiya S, Okamoto I

A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib.

Thorac Cancer 15(5): 415-418, 2024Pubmed

Yamamoto Y, Shibahara D, Mori T, Otsubo K, Shiraishi Y, Yoneshima Y, Iwama E, Tanaka K, Oda Y, Okamoto I

Tracheomediastinal fistula induced by concurrent chemoradiotherapy in small cell lung cancer: A case report and literature review.

Thorac Cancer 15(13): 1106-1111, 2024Pubmed

Nakajima M, Tanaka K, Yoneshima Y, Yamashita S, Shibahara D, Iwama E, Okamoto I

YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells.

Biochem Biophys Res Commun 681: 120-126, 2023Pubmed

Okamura K, Inoue H, Tanaka K, Ikematsu Y, Furukawa R, Ota K, Yoneshima Y, Iwama E, Okamoto I

Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma.

Cancer Sci 114(3): 1095-1107, 2023Pubmed

Shibahara D, Akanuma N, Kobayashi SI, Heo E, Ando M, Fujii M, Jiang F, Prin PN, Pan G, Wong KK, Costa DB, Bararia D, Tenen DG, Watanabe H, Kobayashi SS

TIP60 is required for tumorigenesis in non-small cell lung cancer.

Cancer Sci 114(6): 2400-2413, 2023Pubmed

Nakanishi T, Yoneshima Y, Okamura K, Yanagihara T, Hashisako M, Iwasaki T, Haratake N, Mizusaki S, Ota K, Iwama E, Takenaka T, Tanaka K, Yoshizumi T, Oda Y, Okamoto I

MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma.

Cancer Sci 114(10): 4101-4113, 2023Pubmed

Hirayama A, Tanaka K, Tsutsumi H, Nakanishi T, Yamashita S, Mizusaki S, Ishii Y, Ota K, Yoneshima Y, Iwama E, Okamoto I

Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1β.

Front Immunol 14: 1192861, 2023Pubmed

Tsutumi H, Iwama E, Ibusuki R, Shimauchi A, Ota K, Yoneshima Y, Inoue H, Tanaka K, Nakanishi Y, Okamoto I

Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers.

Lung Cancer 175: 101-111, 2023Pubmed

Tsutsumi H, Inoue H, Shiraishi Y, Hirayama A, Nakanishi T, Ando H, Nakajima M, Shinozaki S, Ogata H, Okamura K, Kimura S, Ogawa T, Ota K, Yoneshima Y, Tanaka K, Hamada N, Okamoto I, Iwama E

Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors.

Lung Cancer 181: 107264, 2023Pubmed

Iwama E, Yamamoto H, Okubo F, Ijichi K, Ibusuki R, Shiaraishi Y, Yoneshima Y, Tanaka K, Oda Y, Okamoto I

Evaluation of appropriate conditions for Oncomine DxTT testing of FFPE specimens for driver gene alterations in non-small cell lung cancer.

Thorac Cancer 14(23): 2288-2296, 2023Pubmed

Nakashima T, Shiraishi Y, Shiota A, Yoneshima Y, Iwama E, Tanaka K, Okamoto I

Afatinib-induced bronchiolitis obliterans.

Curr Probl Cancer 10: 100231, 2023Article

Isa K, Tanaka K, Shiraishi Y, Yoneshima Y, Iwama E, Okamoto I

Osimertinib failure followed by successful treatment of afatinib in a patient with compound uncommon, G719S and V834L mutations.

Curr Probl Cancer 10: 100236, 2023Article

Tsuneoka K, Tanaka K, Shimauchi A, Inoue S, Yoneshima Y, Ikegame S, Harada E, Okamoto I

A Case of Obstructing Bronchial Aspergillosis in a Patient Receiving Cytotoxic Chemotherapy and Inhaled Corticoid Therapy.

RESPEND 1(2): 105-108, 2023Article

Shiraishi Y, Sekino Y, Horinouchi H, Ohe Y, Okamoto I

High incidence of cytokine release syndrome in patients with advanced NSCLC treated with nivolumab plus ipilimumab.

Ann Oncol 34(11): 1064-1065, 2023Pubmed